US2009074661A1PendingUtilityA1

Anti-il-22ra antibodies and binding partners and methods of using in inflammation

67
Assignee: ZYMOGENETICS INCPriority: Mar 24, 2003Filed: Jul 21, 2008Published: Mar 19, 2009
Est. expiryMar 24, 2023(expired)· nominal 20-yr term from priority
Inventors:Wenfeng XuWayne R. KindsvogelYasmin A. ChandrasekherStacey R. DillonJoyce M. LehnerAnthony W. SiadakPallavur V. SivakumarMargaret D. Moore
A61P 37/02A61P 7/00A61P 43/00A61P 37/00A61P 37/08A61P 37/04A61P 31/04A61P 31/00A61P 29/00C07K 2317/73A61P 19/02C07K 14/54C07K 2317/34A61P 17/00A61P 17/06A61P 11/00C07K 16/2866C07K 16/244A61P 11/06A61K 2039/505A61P 1/00C07K 2319/30C07K 2319/00A61P 1/04C07K 14/7155C07K 16/00C07K 16/24
67
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to blocking, inhibiting, reduceing, antagonizing or neutralizing the activity of IL-22, IL-20, or both IL-20 and IL-22 polypeptide molecules. IL-20 and IL-22 are cytokines that are involved in inflammatory processes and human disease. IL-22RA (zcytor11) is a common receptor for IL-20 and IL-22. The present invention includes anti-IL-22RA antibodies and binding partners, as well as methods for antagonizing IL-22 or both IL-20 and IL-22 using such antibodies and binding partners.

Claims

exact text as granted — not AI-modified
1 . An antibody or antigen-binding fragment thereof that can compete with a monoclonal antibody expressed by a hybridoma selected from the group consisting of:
 (a) the hybridoma clone R2.1.1G11.1 (ATCC Patent Deposit Designation [PTA-6035]);   (b) the hybridoma clone R2.1.5F4.1 (ATCC Patent Deposit Designation [PTA-6024]);   (c) the hybridoma clone R2.1.5H8.1 (ATCC Patent Deposit Designation [PTA-6025]);   (d) the hybridoma clone R2.1.12G7.1 (ATCC Patent Deposit Designation [PTA-6036]);   (e) the hybridoma clone R2.1.13C8.1 (ATCC Patent Deposit Designation PTA-5037);   (f) the hybridoma clone R2.1.15E2.1 (ATCC Patent Deposit Designation [PTA-6038]);   (g) the hybridoma clone R2.1.16C 11.1 (ATCC Patent Deposit Designation [PTA-6039]);   (h) the hybridoma clone R2.1.18C8.1 (ATCC Patent Deposit Designation [PTA-6048]); and   (i) the hybridoma clone R2.1.21G8.2(ATCC Patent Deposit Designation [PTA-6111]) for binding to the polypeptides of SEQ ID NO:2 or SEQ ID NO:3.   
     
     
         2 . The antibody or antigen-binding fragment according to  claim 1 , wherein the antibody or antigen-binding fragment binds to SEQ ID NO:2 or SEQ ID NO:3. 
     
     
         3 . The antibody or antigen-binding fragment according to  claim 1 , wherein the antibody or antigen-binding fragment reduces or neutralizes the pro-inflammatory activity of either IL-20 (SEQ ID NO:2 or 3) or IL-22 (SEQ ID NO:6). 
     
     
         4 . The antibody or antigen-binding fragment according to  claim 1 , wherein the antibody or antigen-binding fragment reduces or neutralizes the pro-inflammatory activity of IL-20 (SEQ ID NO:2 or 3) and IL-22 (SEQ ID NO:6). 
     
     
         5 . The antibody or antigen-binding fragment according to  claim 1 , wherein the antibody or antigen-binding fragment is pegylated. 
     
     
         6 . The antibody or antigen-binding fragment according to  claim 1 , wherein the antibody or antigen-binding fragment further comprises a radionuclide, enzyme, substrate, cofactor, fluorescent marker, chemiluminescent marker, peptide tag, magnetic particle, drug, or toxin. 
     
     
         7 . A pharmaceutical composition comprising the antibody or antigen-binding fragment according to  claim 1 . 
     
     
         8 . An antibody or antigen-binding fragment thereof, wherein the antibody or antibody-binding fragment thereof is expressed by a hybridoma selected from the group consisting of:
 (a) the hybridoma clone R2.1.1 G11. I (ATCC Patent Deposit Designation [PTA-6035]);   (b) the hybridoma clone R2.1.5F4.1 (ATCC Patent Deposit Designation [PTA-6024]);   (c) the hybridoma clone R2.1.5H8.1 (ATCC Patent Deposit Designation [PTA-6025]);   (d) the hybridoma clone R2.1.12G7.1 (ATCC Patent Deposit Designation [PTA-6036]);   (e) the hybridoma clone R2.1.13C8.1 (ATCC Patent Deposit Designation PTA-5037);   (f) the hybridoma clone R2.1.15E2.1 (ATCC Patent Deposit Designation [PTA-6038]);   (g) the hybridoma clone R2.1.16C 11.1 (ATCC Patent Deposit Designation [PTA-6039]);   (h) the hybridoma clone R2.1.18C8.1 (ATCC Patent Deposit Designation [PTA-6048]); and   (i) the hybridoma clone R2.1.21G8.2(ATCC Patent Deposit Designation [PTA-6111]).   
     
     
         9 . The antibody or antigen-binding fragment according to  claim 8 , wherein the antibody or antigen-binding fragment reduces or neutralizes the pro-inflammatory activity of either IL-20 (SEQ ID NO:2 or 3) or IL-22 (SEQ ID NO:6). 
     
     
         10 . The antibody or antigen-binding fragment according to  claim 8 , wherein the antibody or antigen-binding fragment reduces or neutralizes the pro-inflammatory activity of IL-20 (SEQ ID NO:2 or 3) and IL-22 (SEQ ID NO:6) 
     
     
         11 . The antibody or antigen-binding fragment according to  claim 8 , wherein the antibody or antigen-binding fragment is pegylated. 
     
     
         12 . The antibody or antigen-binding fragment according to  claim 8 , wherein the antibody or antigen-binding fragment further comprises a radionuclide, enzyme, substrate, cofactor, fluorescent marker, chemiluminescent marker, peptide tag, magnetic particle, drug, or toxin. 
     
     
         13 . A pharmaceutical composition comprising the antibody or antigen-binding fragment according to  claim 8 . 
     
     
         14 . An immunoconjugate comprising a monoclonal antibody expressed by a hybridoma selected from the group consisting of:
 (a) the hybridoma clone R2.1.1 G11.1 (ATCC Patent Deposit Designation [PTA-6035]);   (b) the hybridoma clone R2.1.5F4.1 (ATCC Patent Deposit Designation [PTA-6024]);   (c) the hybridoma clone R2.1.5H8.1 (ATCC Patent Deposit Designation [PTA-6025]);   (d) the hybridoma clone R2.1.12G7.1 (ATCC Patent Deposit Designation [PTA-6036]);   (e) the hybridoma clone R2.1.13C8.1 (ATCC Patent Deposit Designation PTA-5037);   (f) the hybridoma clone R2.1.15E2.1 (ATCC Patent Deposit Designation [PTA-6038]);   (g) the hybridoma clone R2.1.16C 11.1 (ATCC Patent Deposit Designation [PTA-6039]);   (h) the hybridoma clone R2.1.18C8.1 (ATCC Patent Deposit Designation [PTA-6048]); and   (i) the hybridoma clone R2.1.21G8.2(ATCC Patent Deposit Designation [PTA-6111]).   
     
     
         15 . The immunoconjugate according to  claim 14 , wherein the immunoconjugate reduces or neutralizes the pro-inflammatory activity of either IL-20 (SEQ ID NO:2 or 3) or IL-22 (SEQ ID NO:6). 
     
     
         16 . The immunoconjugate according to  claim 14 , wherein the immunoconjugate reduces or neutralizes the pro-inflammatory activity of IL-20 (SEQ ID NO:2 or 3) and IL-22 (SEQ ID NO:6). 
     
     
         17 . The immunoconjugate according to  claim 14 , wherein the immunoconjugate is pegylated. 
     
     
         18 . The immunoconjugate according to  claim 14 , wherein the immunoconjugate further comprises a radionuclide, enzyme, substrate, cofactor, fluorescent marker, chemiluminescent marker, peptide tag, magnetic particle, drug, or toxin. 
     
     
         19 . A pharmaceutical composition comprising the immunoconjugate according to  claim 14 . 
     
     
         20 . A hybridoma selected from the group consisting of:
 (a) the hybridoma clone R2.1.1 G11.1 (ATCC Patent Deposit Designation [PTA-6035]);   (b) the hybridoma clone R2.1.5F4.1 (ATCC Patent Deposit Designation [PTA-6024]);   (c) the hybridoma clone R2.1.5H8.1 (ATCC Patent Deposit Designation [PTA-6025]);   (d) the hybridoma clone R2.1.12G7.1 (ATCC Patent Deposit Designation [PTA-6036]);   (e) the hybridoma clone R2.1.13C8.1 (ATCC Patent Deposit Designation PTA-5037);   (f) the hybridoma clone R2.1.15E2.1 (ATCC Patent Deposit Designation [PTA-6038]);   (g) the hybridoma clone R2.1.16C11.1 (ATCC Patent Deposit Designation [PTA-6039]);   (h) the hybridoma clone R2.1.18C8.1 (ATCC Patent Deposit Designation [PTA-6048]); and   (i) the hybridoma clone R2.1.21G8.2(ATCC Patent Deposit Designation [PTA-6111]).   
     
     
         21 . A monoclonal antibody expressed by the hybridoma according to  claim 20 . 
     
     
         22 . A method of treating a mammal afflicted with an inflammatory disease in which IL-22RA plays a role, comprising administration of an antibody or antigen-binding fragment thereof expressed by a hybridoma selected from the group consisting of:
 (a) the hybridoma clone R2.1.1 G11.1 (ATCC Patent Deposit Designation [PTA-6035]);   (b) the hybridoma clone R2.1.5F4.1 (ATCC Patent Deposit Designation [PTA-6024]);   (c) the hybridoma clone R2.1.5H8.1 (ATCC Patent Deposit Designation [PTA-6025]);   (d) the hybridoma clone R2.1.12G7.1 (ATCC Patent Deposit Designation [PTA-6036]);   (e) the hybridoma clone R2.1.13C8.1 (ATCC Patent Deposit Designation PTA-5037);   (f) the hybridoma clone R2.1.15E2.1 (ATCC Patent Deposit Designation [PTA-6038]);   (g) the hybridoma clone R2.1.16C11.1 (ATCC Patent Deposit Designation [PTA-6039]);   (h) the hybridoma clone R2.1.18C8.1 (ATCC Patent Deposit Designation [PTA-6048]); and   (i) the hybridoma clone R2.1.21G8.2(ATCC Patent Deposit Designation [PTA-6111]),   wherein the antibody or antigen-binding fragment thereof reduces the inflammation.   
     
     
         23 . The method according to  claim 22 , wherein the disease is a chronic inflammatory disease. 
     
     
         24 . The method according to  claim 23 , wherein the disease is a chronic inflammatory disease selected from the group consisting of inflammatory bowel disease; ulcerative colitis; Crohn's disease; arthritis; psoriatic arthritis; rheumatoid arthritis; and psoriasis. 
     
     
         25 . The method according to  claim 22 , wherein the disease is an acute inflammatory disease. 
     
     
         26 . The method according to  claim 25 , wherein the disease is an acute inflammatory disease selected from the group consisting of endotoxemia; septicemia; toxic shock syndrome; and infectious disease.

Join the waitlist — get patent alerts

Track US2009074661A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.